版本:
中国

BRIEF-Mast reports top-line results from phase 3 study in Sickle Cell Disease

Sept 20 Mast Therapeutics

* Line results from phase 3 study in Sickle Cell Disease

* No statistically significant differences between treatment groups in intent-to-treat population across 2 secondary efficacy endpoints

* Plan to perform an interim analysis of ongoing heart failure trial of Vepoloxamer

* Intend to significantly and immediately reduce operating expenses and continue efforts with AIR001

* Study did not meet its primary efficacy endpoint

* No deaths occurred on study.

* Based on data seen to date, expect will terminate all clinical development of vepoloxamer Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐